>90%
PortfolioOur 2025 integrated portfolio combining biotech and general equities significantly outperformed both the Nasdaq Composite and S&P 500.
Biotech Research You Can Read.Portfolio Moves You Can Act On.
Smarter Biotech, Better Market Decisions
Most investors stop at headlines. We bridge science and market decisions in biotech, then deliver clear entries, exits, and sizing updates you can actually execute.
PhD/MD-Led ResearchTransparent Entries & ExitsWeekly Portfolio Updates
Performance Snapshot
Results thatOutperform the Market.
Last Audited
MAR 2026
Win Rate
72%
Profitable Trades
Benchmark Blend
15%
XBI, NASDAQ BI, Russell 2000, DJIA, S&P 500
Total Transparency Commitment
Recommendations, entry levels, and exits are documented in real time.
The MindReader Framework
Science + Portfolio Process + Risk Control
Biotech investing is strongest when research depth and execution discipline work as one system.
Scientific Edge
PhD/MD-level thesis quality
Translate dense clinical data into actionable probability-weighted views before market consensus catches up.
- Mechanism and endpoint scrutiny
- Trial design and statistical rigor
- Competitive and regulatory context
Portfolio Discipline
Execution over emotion
Every idea includes entry, invalidation, and sizing logic so decisions remain consistent through volatility.
- Risk-adjusted position sizing
- Catalyst calendar alignment
- Documented entry and exit alerts
Premium Access
Unlock Premium PortfoliosPremium Data & Portfolios
Institutional-style portfolio structures, biotech conviction ideas, and risk-managed allocations for serious members.
Fit Check
Who This Is For
Premium portfolios work best for investors who want a process-first approach to biotech conviction.
Ideal For Investors Who:
- Have investing experience and want biotech-specific edge
- Can handle high-risk, high-reward volatility
- Care about science-backed thesis quality
- Prefer independent research over media narratives
- Want clear risk rules for entries and exits
- Think in quarters and years, not quick flips
Not Suitable For:
- Day traders chasing instant momentum
- Investors seeking guaranteed returns
- Anyone unwilling to tolerate biotech volatility
- People ignoring downside and invalidation risk
- Users wanting tips without thesis context
- Short-term speculation with no process discipline
Free Research Desk
Latest Insights
Read concise biotech breakdowns before you decide whether premium portfolio execution is right for you.
Updated FrequentlyView All Articles
Clinical TrialsMarket PositioningCatalyst WatchRisk Context
Science Desk
25 Feb 2026
Understanding Patrick Soon-Shiong’s NANT Cancer Vaccine: A Systems-Level War Map for Cancer
Read Article →
Investing Insight
25 Feb 2026
How our biotech system works.
Read Article →
Food for Thought
21 Feb 2026
The Terrifying Implications of the Microbiome
Read Article →
Investing Insight
21 Feb 2026
The Emperor Has No Clothes
Read Article →
Investors Note
19 Feb 2026
From Analysis to Alpha: The Reality of Emerging Biotech Growth
Read Article →
Investing Insight
10 Feb 2026
Nektar Awakens
Emerging biotech investing is a roller coaster. The author details volatile plays in Nektar and Mindreader, emphasizing conviction despite dips and buyout speculation, seeing strong long-term upside.
Read Article →
Science Desk
10 Jan 2026
How Cancer Vaccines Train the Body to Fight Tumors
Read Article →
Science Desk
29 Dec 2025
The Rise of Bispecific and Trispecific Antibodies in Oncology
Read Article →
Science Desk
26 Jan 2026
Why IL-15 Is Changing Cancer Immunotherapy: The Biology Behind ANKTIVA
Read Article →
Food for Thought
15 Dec 2025
Glycemic Index Fiber the new protein
Read Article →
Food for Thought
29 Dec 2025
Science Discovers the Microbiome
Read Article →
Research Engine
How a Thesis Becomes a Portfolio Move
A transparent five-step framework designed to reduce emotional decisions and increase probability-weighted outcomes.
STEP 01
Screen the Universe
Filter biotech opportunities using catalyst timing, valuation dislocations, and scientific relevance.
STEP 02
Validate the Science
Break down mechanism, trial quality, endpoints, and probability-adjusted outcomes before conviction builds.
STEP 03
Model the Trade
Define entry zones, invalidation levels, and allocation size based on downside tolerance and portfolio context.
STEP 04
Execute With Discipline
Publish member alerts when setups trigger and update thesis quality as new data or regulation events emerge.
STEP 05
Review and Reallocate
Track outcomes transparently, harvest gains, cut weak theses, and recycle capital into stronger asymmetric setups.
Member Perspective
Why Investors Upgrade to Premium
The goal is not more noise. It is better conviction, cleaner execution, and documented decision quality.
The biggest value is clarity. I know why we enter, what invalidates the thesis, and when to reduce risk.
Long-Horizon Member
Biotech-Focused Investor
Free articles helped me learn. Premium alerts gave me execution discipline I did not have before.
PRO Subscriber
Growth Portfolio Builder
The blend of science and risk controls makes this different from generic stock newsletters.
Premium Member
Fundamental Investor